{
  "symbol": "ANIP",
  "company": "ANI Pharmaceuticals, Inc.",
  "generated_at": "2026-06-24T07:36:44.739Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-11T07:58:09.644Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Anti-signals (insider selling cluster ~$1.1M and active product recall) trigger the mandatory skip gate. The composite score of 40 falls below the 45 threshold, and the dossier lacks the necessary smart-money confirmation or structural edge to override the selling and quality concerns.",
      "trigger": "[insider_cluster_universe] 5 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-11T07:58:09.624Z",
      "skip": true,
      "reason": "Anti-signals (insider selling cluster ~$1.1M and active product recall) trigger the mandatory skip gate. The composite score of 40 falls below the 45 threshold, and the dossier lacks the necessary smart-money confirmation or structural edge to override the selling and quality concerns.",
      "score": 40,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 15,
        "mispricing": 9,
        "quality": 10,
        "technical": 6
      },
      "debug_path": "drafts/2026-06-11-ANIP.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-11T07:56:55.604Z",
      "summary": "ANIP triggered on a Form 4 cluster (5+ filings in 14 days), but investigation reveals the cluster consists entirely of routine restricted stock award (RSA) grants to non-employee directors vesting on a scheduled calendar date — no open-market purchases from CEO or CFO. The one officer transaction was the SVP/CFO exercising old options and immediately selling via a pre-set 10b5-1 plan, not a discretionary vote of confidence. Separately, Patrick Walsh (Director) executed two large open-market sales in May (~14k shares at ~$80.63–$80.75), an anti-signal. Q1 earnings beat consensus by +57.8% and management raised full-year 2026 revenue guidance to $1.08B–$1.14B, with Cortrophin Gel growing 42% YoY. The stock trades at only ~9.75x forward earnings despite 20%+ revenue growth and ~7.5% FCF yield — a clear valuation anomaly relative to specialty pharmaceutical peers at 12–18x.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 21,
      "walltime_min": 12,
      "debug_path": "dossiers/2026-06-11-ANIP.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "ANIP",
    "call": "BUY",
    "confidence": 5,
    "score": 6,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_up": "+1 (23.6%)",
      "rsi_neutral": "0 (57.1)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (9d ago)",
      "from_high": "0 (-16.1%)"
    },
    "summary": "BUY (score +6) · 12-1 mom 23.6% · RSI 57.1 · above_both · -16.1% from high",
    "last_close": 82.94,
    "one_month_ago_close": 82.77,
    "twelve_month_ago_close": 66.98,
    "twelve_one_momentum_pct": 23.57,
    "rsi_14": 57.1,
    "ma_stack": "above_both",
    "from_period_high_pct": -16.06,
    "period_high": 98.81,
    "price_targets": {
      "bear": 69.17,
      "fair": 91.96,
      "bull": 124,
      "bear_return_pct": -16.6,
      "fair_return_pct": 10.9,
      "bull_return_pct": 49.5,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 100,
        "target_mean": 112.71429,
        "target_high": 124,
        "analyst_count": 7
      }
    },
    "generated_at": "2026-06-24T07:36:44.735Z"
  }
}